PDF herunterladen
Planta Med 2023; 89(12): 1138-1146
DOI: 10.1055/a-2103-3230
Biological and Pharmacological Activity
Original Papers

Hop-derived Humulinones Reveal Protective Effects in in vitro Models of Hepatic Steatosis, Inflammation and Fibrosis

Abdo Mahli
1   Institute of Biochemistry, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
2   Department of Pharmacology and Biomedical Sciences, Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan
,
Wolfgang E. Thasler
3   Human Tissue and Cell Research-Services GmbH, Planegg/Martinsried, Germany
,
Martin Biendl
4   Hopsteiner, Hallertauer Hopfenveredelung GmbH, Mainburg, Germany
,
Claus Hellerbrand
1   Institute of Biochemistry, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
› Institutsangaben
› Weitere Informationen
    Lizenzen und Reprints

Abstract

Nonalcoholic fatty liver disease (NAFLD) is emerging as leading cause of liver disease worldwide. Specific pharmacologic therapy for NAFLD is a major unmet medical need. Recently, iso-alpha acids, hop-derived bitter compounds in beer, have been shown to beneficially affect NAFLD pathology. Humulinones are further hop derived bitter acids particularly found in modern styles of beer. So far, biological effects of humulinones have been unknown. Here, we investigated the effect of humulinones in in vitro models for hepatic steatosis, inflammation and fibrosis. Humulinones dose-dependently inhibited fatty acid induced lipid accumulation in primary human hepatocytes. Humulinones reduced the expression of fatty acid uptake transporter CD36 and key enzymes of (de novo) lipid synthesis. Conversely, humulinones increased the expression of FABP1, CPT1 and ACOX1, indicative for increased lipid combustion. Furthermore, humulinones ameliorated steatosis induced pro-inflammatory gene expression. Furthermore, humulinones significantly reduced the expression of pro-inflammatory and pro-fibrogenic factors in control as well as lipopolysaccharide treated activated hepatic stellate cells, which play a key role in hepatic fibrosis. In conclusion, humulinones beneficially affect different pathophysiological steps of NAFLD. Our data suggest humulinones as promising therapeutic agents for the prevention and treatment of NAFLD.

Key words

Cannabaceae - Humulus lupulus L - humulinones - nonalcoholic fatty liver disease - steatosis - inflammation - fibrosis


Publikationsverlauf

Eingereicht: 09. Januar 2023

Angenommen nach Revision: 26. Mai 2023

Artikel online veröffentlicht:
21. Juni 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol 2014; 28: 637-653
    CrossrefPubMedGoogle Scholar
  • 2 Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021; 184: 2537-2564
    CrossrefPubMedGoogle Scholar
  • 3 Mahli A, Koch A, Fresse K, Schiergens T, Thasler WE, Schonberger C, Bergheim I, Bosserhoff A, Hellerbrand C. Iso-alpha acids from hops (Humulus lupulus) inhibit hepatic steatosis, inflammation, and fibrosis. Lab Invest 2018; 98: 1614-1626
    CrossrefPubMedGoogle Scholar
  • 4 Hege M, Jung F, Sellmann C, Jin C, Ziegenhardt D, Hellerbrand C, Bergheim I. An iso-alpha-acid-rich extract from hops (Humulus lupulus) attenuates acute alcohol-induced liver steatosis in mice. Nutrition 2018; 45: 68-75
    CrossrefPubMedGoogle Scholar
  • 5 Hall AJ, Babish JG, Darland GK, Carroll BJ, Konda VR, Lerman RH, Bland JS, Tripp ML. Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. Phytochemistry 2008; 69: 1534-1547
    CrossrefPubMedGoogle Scholar
  • 6 Takase T, Toyoda T, Kobayashi N, Inoue T, Ishijima T, Abe K, Kinoshita H, Tsuchiya Y, Okada S. Dietary iso-alpha-acids prevent acetaldehyde-induced liver injury through Nrf2-mediated gene expression. PLoS One 2021; 16: e0246327
    CrossrefPubMedGoogle Scholar
  • 7 Kunimune T, Shellhammer TH. Foam-stabilizing effects and cling formation patterns of iso-alpha-acids and reduced iso-alpha-acids in lager beer. J Agric Food Chem 2008; 56: 8629-8634
    CrossrefPubMedGoogle Scholar
  • 8 Taniguchi Y, Matsukura Y, Ozaki H, Nishimura K, Shindo K. Identification and quantification of the oxidation products derived from alpha-acids and beta-acids during storage of hops (Humulus lupulus L.). J Agric Food Chem 2013; 61: 3121-3130
    CrossrefPubMedGoogle Scholar
  • 9 Maye JP, Smith R, Lecker J. Formation of humulinones in hops and hop pellets and its implication for dry-hopped beers. TechQ Master Brew Assoc Am 2016; 53: 23-27
    PubMedGoogle Scholar
  • 10 Hahn CD, Lafontaine SR, Pereira CB, Shellhammer TH. Evaluation of nonvolatile chemistry affecting sensory bitterness intensity of highly hopped beers. J Agric Food Chem 2018; 66: 3505-3513
    CrossrefPubMedGoogle Scholar
  • 11 Oladokun O, Tarrega A, James S, Smart K, Hort J, Cook D. The impact of hop bitter acid and polyphenol profiles on the perceived bitterness of beer. Food Chem 2016; 205: 212-220
    CrossrefPubMedGoogle Scholar
  • 12 Taniguchi Y, Taniguchi H, Yamada M, Matsukura Y, Koizumi H, Furihata K, Shindo K. Analysis of the components of hard resin in hops (Humulus lupulus L.) and structural elucidation of their transformation products formed during the brewing process. J Agric Food Chem 2014; 62: 11602-11612
    CrossrefPubMedGoogle Scholar
  • 13 Maye JP, Smith R. Dry hopping and its effects on the international bitterness unit test and beer bitterness. MBAA TQ 2016; 53: 134-136
    PubMedGoogle Scholar
  • 14 Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-1351
    CrossrefPubMedGoogle Scholar
  • 15 Dorn C, Riener MO, Kirovski G, Saugspier M, Steib K, Weiss TS, Gabele E, Kristiansen G, Hartmann A, Hellerbrand C. Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int J Clin Exp Pathol 2010; 3: 505-514
    PubMedGoogle Scholar
  • 16 Wobser H, Dorn C, Weiss TS, Amann T, Bollheimer C, Buttner R, Scholmerich J, Hellerbrand C. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res 2009; 19: 996-1005
    CrossrefPubMedGoogle Scholar
  • 17 Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, Persico M, Colombo A, Monasterolo F, Casadei-Giunchi D, Desiderio F, Stroffolini T, Sacchini V, Decensi A, Veronesi U. Incidence and risk factors for non-alcoholic steatohepatitis: Prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005; 330: 932
    CrossrefPubMedGoogle Scholar
  • 18 Kucera O, Al-Dury S, Lotkova H, Rousar T, Rychtrmoc D, Cervinkova Z. Steatotic rat hepatocytes in primary culture are more susceptible to the acute toxic effect of acetaminophen. Physiol Res 2012; 61 Suppl 2: S93-101
    CrossrefPubMedGoogle Scholar
  • 19 Wang GQ, Bonkovsky HL, de Lemos A, Burczynski FJ. Recent insights into the biological functions of liver fatty acid binding protein 1. J Lipid Res 2015; 56: 2238-2247
    CrossrefPubMedGoogle Scholar
  • 20 Pettinelli P, Videla LA. Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: An additional reinforcing lipogenic mechanism to SREBP-1c induction. J Clin Endocrinol Metab 2011; 96: 1424-1430
    CrossrefPubMedGoogle Scholar
  • 21 Matsuzaka T, Atsumi A, Matsumori R, Nie T, Shinozaki H, Suzuki-Kemuriyama N, Kuba M, Nakagawa Y, Ishii K, Shimada M, Kobayashi K, Yatoh S, Takahashi A, Takekoshi K, Sone H, Yahagi N, Suzuki H, Murata S, Nakamuta M, Yamada N, Shimano H. Elovl6 promotes nonalcoholic steatohepatitis. Hepatology 2012; 56: 2199-2208
    CrossrefPubMedGoogle Scholar
  • 22 Bahcecioglu IH, Yalniz M, Ataseven H, Ilhan N, Ozercan IH, Seckin D, Sahin K. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology 2005; 52: 1549-1553
    PubMedGoogle Scholar
  • 23 Ito S, Yukawa T, Uetake S, Yamauchi M. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis. Alcohol Clin Exp Res 2007; 31: S83-87
    CrossrefPubMedGoogle Scholar
  • 24 Jamwal R, de la Monte SM, Ogasawara K, Adusumalli S, Barlock BB, Akhlaghi F. Nonalcoholic fatty liver disease and diabetes are associated with decreased CYP3A4 protein expression and activity in human liver. Mol Pharm 2018; 15: 2621-2632
    CrossrefPubMedGoogle Scholar
  • 25 Hellerbrand C. Hepatic stellate cells–the pericytes in the liver. Pflugers Arch 2013; 465: 775-778
    CrossrefPubMedGoogle Scholar
  • 26 Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 2017; 14: 397-411
    CrossrefPubMedGoogle Scholar
  • 27 Chen M, Liu J, Yang W, Ling W. Lipopolysaccharide mediates hepatic stellate cell activation by regulating autophagy and retinoic acid signaling. Autophagy 2017; 13: 1813-1827
    CrossrefPubMedGoogle Scholar
  • 28 Harte AL, da Silva NF, Creely SJ, McGee KC, Billyard T, Youssef-Elabd EM, Tripathi G, Ashour E, Abdalla MS, Sharada HM, Amin AI, Burt AD, Kumar S, Day CP, McTernan PG. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond) 2010; 7: 15
    CrossrefPubMedGoogle Scholar
  • 29 Seki E, De Minicis S, Gwak GY, Kluwe J, Inokuchi S, Bursill CA, Llovet JM, Brenner DA, Schwabe RF. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest 2009; 119: 1858-1870
    PubMedGoogle Scholar
  • 30 Yoshiji H, Kuriyama S, Miyamoto Y, Thorgeirsson UP, Gomez DE, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Thorgeirsson SS, Fukui H. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 2000; 32: 1248-1254
    CrossrefPubMedGoogle Scholar
  • 31 Benyon RC, Iredale JP, Goddard S, Winwood PJ, Arthur MJP. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996; 110: 821-831
    CrossrefPubMedGoogle Scholar
  • 32 Preaux AM, Mallat A, Nhieu JT, DʼOrtho MP, Hembry RM, Mavier P. Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions. Hepatology 1999; 30: 944-950
    CrossrefPubMedGoogle Scholar
  • 33 Thompson KJ, McKillop IH, Schrum LW. Targeting collagen expression in alcoholic liver disease. World J Gastroenterol 2011; 17: 2473-2481
    CrossrefPubMedGoogle Scholar
  • 34 Cattoor K, Remon JP, Boussery K, Van Bocxlaer J, Bracke M, De Keukeleire D, Deforce D, Heyerick A. Bioavailability of hop-derived iso-alpha-acids and reduced derivatives. Food Funct 2011; 2: 412-422
    CrossrefPubMedGoogle Scholar
  • 35 Todisco S, Santarsiero A, Convertini P, De Stefano G, Gilio M, Iacobazzi V, Infantino V. PPAR alpha as a metabolic modulator of the liver: Role in the pathogenesis of nonalcoholic steatohepatitis (NASH). Biology (Basel) 2022; 11:
    PubMedGoogle Scholar
  • 36 Lim WS, Ng DL, Kor SB, Wong HK, Tengku-Muhammad TS, Choo QC, Chew CH. Tumour necrosis factor alpha down-regulates the expression of peroxisome proliferator activated receptor alpha (PPARalpha) in human hepatocarcinoma HepG2 cells by activation of NF-kappaB pathway. Cytokine 2013; 61: 266-274
    CrossrefPubMedGoogle Scholar
  • 37 Atshaves BP, Storey SM, Petrescu A, Greenberg CC, Lyuksyutova OI, Smith 3rd R, Schroeder F. Expression of fatty acid binding proteins inhibits lipid accumulation and alters toxicity in L cell fibroblasts. Am J Physiol Cell Physiol 2002; 283: C688-703
    CrossrefPubMedGoogle Scholar
  • 38 Ek-Von Mentzer BA, Zhang F, Hamilton JA. Binding of 13-HODE and 15-HETE to phospholipid bilayers, albumin, and intracellular fatty acid binding proteins. implications for transmembrane and intracellular transport and for protection from lipid peroxidation. J Biol Chem 2001; 276: 15575-15580
    CrossrefPubMedGoogle Scholar
  • 39 Huang Z, Wang M, Liu L, Peng J, Guo C, Chen X, Huang L, Tan J, Yang G. Transcriptional repression of CYP3A4 by increased miR-200a-3 p and miR-150–5 p promotes steatosis in vitro . Front Genet 2019; 10: 484
    CrossrefPubMedGoogle Scholar
  • 40 Friedman SL. Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-172
    CrossrefPubMedGoogle Scholar
  • 41 Acharya P, Chouhan K, Weiskirchen S, Weiskirchen R. Cellular mechanisms of liver fibrosis. Front Pharmacol 2021; 12: 671640
    CrossrefPubMedGoogle Scholar
  • 42 Cattoor K, Dresel M, De Bock L, Boussery K, Van Bocxlaer J, Remon JP, De Keukeleire D, Deforce D, Hofmann T, Heyerick A. Metabolism of hop-derived bitter acids. J Agric Food Chem 2013; 61: 7916-7924
    CrossrefPubMedGoogle Scholar
  • 43 Maye JP, Leker J, Smith R. Preparation of Dicyclohexylamine Humulinones and Dicyclohexylamine Hulupones. J Am Soc Brew Chem 2016; 74: 57-60
    PubMedGoogle Scholar
  • 44 Lee SM, Schelcher C, Laubender RP, Fröse N, Thasler RM, Schiergens TS, Mansmann U, Thasler WE. An algorithm that predicts the viability and the yield of human hepatocytes isolated from remnant liver pieces obtained from liver resections. PLoS One 2014; 9: e107567
    CrossrefPubMedGoogle Scholar
  • 45 Lee SM, Schiergens TS, Demmel M, Thasler RM, Thasler WE. Isolation of hepatocytes and stellate cells from a single piece of human liver. Methods Mol Biol 2017; 1506: 247-258
    CrossrefPubMedGoogle Scholar
  • 46 Muhlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, Lock G, Scholmerich J, Hellerbrand C. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003; 125: 1085-1093
    CrossrefPubMedGoogle Scholar
  • 47 Mahli A, Thasler WE, Patsenker E, Muller S, Stickel F, Muller M, Seitz HK, Cederbaum AI, Hellerbrand C. Identification of cytochrome CYP2E1 as critical mediator of synergistic effects of alcohol and cellular lipid accumulation in hepatocytes in vitro. Oncotarget 2015; 6: 41464-41478
    CrossrefPubMedGoogle Scholar
  • 48 Sommer J, Mahli A, Freese K, Schiergens TS, Kuecuekoktay FS, Teufel A, Thasler WE, Muller M, Bosserhoff AK, Hellerbrand C. Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice. Oncotarget 2017; 8: 13059-13072
    CrossrefPubMedGoogle Scholar
  • 49 Mahli A, Koch A, Czech B, Peterburs P, Lechner A, Haunschild J, Müller M, Hellerbrand C. Hepatoprotective effect of oral application of a silymarin extract in carbon tetrachloride-induced hepatotoxicity in rats. Clinical Phytoscience 2015; 1: 5
    CrossrefPubMedGoogle Scholar
  • 50 Mahli A, Saugspier M, Koch A, Sommer J, Dietrich P, Lee S, Thasler R, Schulze-Luehrmann J, Luehrmann A, Thasler WE, Muller M, Bosserhoff A, Hellerbrand C. ERK activation and autophagy impairment are central mediators of irinotecan-induced steatohepatitis. Gut 2018; 67: 746-756
    PubMedGoogle Scholar